Nicholas G Luksha

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Early identification of monoclonal antibody candidates whose development, as high concentration (≥100 mg/mL) drug products, could prove challenging, due to high viscosity, can help define strategies for candidate engineering and selection. Concentration dependent viscosities of 11 proprietary mAbs were measured. Sequence and structural features of the(More)
Early stage developability assessments of monoclonal antibody (mAb) candidates can help reduce risks and costs associated with their product development. Forecasting viscosity of highly concentrated mAb solutions is an important aspect of such developability assessments. Reliable predictions of concentration-dependent viscosity behaviors for mAb solutions(More)
  • 1